Drug resistance reversed by silencing LIM domain‑containing protein 1 expression in colorectal carcinoma

Chen,Zhangxing; Zhu,Xiaosan; Xie,Tao; Xie,Junpei; Quo,Kong; Liu,Xiang

doi:10.3892/ol.2014.2155

Drug resistance reversed by silencing LIM domain‑containing protein 1 expression in colorectal carcinoma

Authors:
- Zhangxing Chen
- Xiaosan Zhu
- Tao Xie
- Junpei Xie
- Kong Quo
- Xiang Liu
View Affiliations

Affiliations: Department of Gastroenterology, The 174th Hospital of the PLA, Xiamen, Fujian 361003, P.R. China, Center for Clinical and Translational Science, Creighton University School of Medicine, Omaha, NE 68178, USA
Published online on: May 19, 2014 https://doi.org/10.3892/ol.2014.2155
Pages: 795-798

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of LIM domain‑containing protein 1 (LIMD1) in the multidrug resistance of colorectal carcinoma (CRC) has not yet been established. The aim of the current study was to investigate the chemosensitivity of CRC multidrug‑resistant (MDR) cells following the silencing of LIMD1. The MDR phenotypic Colo205 and HCT‑8 cell lines were examined, which were established by exposure to increasing doses of 5‑fluorouracil (5‑FU) over a period of one year. LIMD1 siRNA constructs were transfected into CRC MDR cells and the phenotypic effects were determined comprehensively. The Colo205 and HCT‑8 cell lines were more resistant to 5‑FU compared with their respective parental cell lines. In addition, the two MDR cell types expressed significantly more LIMD1 compared with their parental lines. The stably transfected cells showed various degrees of reversal of the MDR phenotype, and 5‑FU‑induced apoptosis was increased in the transfected cells compared with the controls. In conclusion, RNA interference targeting LIMD1 may present a novel therapeutic option for CRC.

View Figures

View References

1	Levin TR and Corley DA: Colorectal-cancer screening - coming of age. N Engl J Med. 369:1164–1166. 2013.
2	Mastalier B, Tihon C, Ghiţă B, Botezatu C, Deaconescu V, Mandisodza P, Drăghici C and Simion S: Surgical treatment of colon cancer: Colentina surgical clinic experience. J Med Life. 5:348–353. 2012.
3	Ito Y, Yamada Y, Asada K, Ushijima T, Iwasa S, Kato K, Hamaguchi T and Shimada Y: EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients. J Cancer Res Clin Oncol. 139:1391–1396. 2013.
4	Zhu XS, Dai YC, Chen ZX, Xie JP, Zeng W, Lin YY and Tan QH: Knockdown of ECHS1 protein expression inhibits hepatocellular carcinoma cell proliferation via suppression of Akt activity. Crit Rev Eukaryot Gene Expr. 23:275–282. 2013.
5	Lin YL and Pasero P: Interference between DNA replication and transcription as a cause of genomic instability. Curr Genomics. 13:65–73. 2012.
6	Magge D, Zureikat AH, Bartlett DL, Holtzman MP, Choudry HA, Beumer JH, Pingpank JF, Holleran JL, Strychor S, Cunningham DE, et al: A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer. Ann Surg Oncol. 20:2180–2187. 2013.
7	Mirakhorli M, Rahman SA, Abdullah S, Vakili M, Rozafzon R and Khoshzaban A: Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy. Mol Med Rep. 7:613–617. 2013.
8	Sharp TV, Munoz F, Bourboulia D, Presneau N, Darai E, Wang HW, Cannon M, Butcher DN, Nicholson AG, Klein G, et al: LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription. Proc Natl Acad Sci USA. 101:16531–16536. 2004.
9	Xu K, Liang X, Shen K, Sun L, Cui D, Zhao Y, Tian J, Ni L and Liu J: MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell Res. 318:2168–2177. 2012.
10	Maddalena F, Laudiero G, Piscazzi A, Secondo A, Scorziello A, Lombardi V, Matassa DS, Fersini A, Neri V, Esposito F and Landriscina M: Sorcin induces a drug-resistant phenotype in human colorectal cancer by modulating Ca(2+) homeostasis. Cancer Res. 71:7659–7669. 2011.
11	Andersen V, Ostergaard M, Christensen J, Overvad K, Tjønneland A and Vogel U: Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 9:4072009.
12	Andersen V, Agerstjerne L, Jensen D, Østergaard M, Saebø M, Hamfjord J, Kure E and Vogel U: The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study. BMC Med Genet. 10:182009.
13	Vilaça N, Amorim R, Machado AF, Parpot P, Pereira MF, Sardo M, Rocha J, Fonseca AM, Neves IC and Baltazar F: Potentiation of 5-fluorouracil encapsulated in zeolites as drug delivery systems for in vitro models of colorectal carcinoma. Colloids Surf B Biointerfaces. 112:237–244. 2013.